176 results on '"Mittal, Abhenil"'
Search Results
2. The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma
3. Benefit of adjuvant bisphosphonates in early breast cancer treated with contemporary systemic therapy: A meta-analysis of randomized control trials
4. Surrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls
5. Controversies and Challenges in the Management of Osteosarcoma—an Indian Perspective
6. Three-year disease-free survival in randomized trials of neoadjuvant chemotherapy and HER2-targeted therapy in breast cancer: A meta-analysis
7. An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy
8. The Survival Outcomes of the Metastatic Nonclear Cell Renal Cell Carcinoma in the Immunotherapy Era: Princess Margaret Cancer Centre Experience
9. Association between control group therapy and magnitude of clinical benefit of cancer drugs
10. Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center
11. Comparison of outcomes for Hispanic and non‐Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma Database.
12. ASO Visual Abstract: Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center
13. ASO Author Reflections: Germline Testing for All Patients With Breast Cancer: Has the Time Finally Come?
14. Utility of ctDNA in predicting relapse in solid tumors after curative therapy: a meta-analysis
15. Prognostic value of human leukocyte antigen G expression in solid tumors: a systematic review and meta-analysis
16. Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care
17. Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer
18. Abstract P4-07-02: Toxicity profile of single agent trastuzumab deruxtecan in solid tumors: A meta-analysis
19. Abstract P2-02-01: Benefit of adjuvant bisphosphonates in early breast cancer treated with contemporary systemic therapy: A meta-analysis of randomized control trials
20. The survival outcomes of metastatic non-clear cell renal cell carcinoma in the immunotherapy era: Princess Margaret Cancer Centre (PMCC) experience.
21. Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review
22. Isolated Lymph Node Amyloidosis: Response Assessment to Chemotherapy on Serial 18F-FDG PET/CT Scans
23. Primary plasma cell leukaemia in a 20-year young adult male: a rare presentation
24. Association between control group therapy and magnitude of clinical benefit of cancer drugs.
25. Spectrum and management of breast cancer patients with variant of uncertain significance mutations at a tertiary care centre in North India
26. Diffuse Large B-Cell Lymphoma presenting as isolated pleural effusion with excellent response to R-PEPC regimen
27. Real-world outcomes of patients with human epidermal growth factor 2 (HER2)–positive breast cancer receiving neoadjuvant therapy without adjuvant ado-trastuzumab emtansine (T-DM1).
28. Changes in circulating tumor DNA (ctDNA) and outcomes in solid tumors treated with immune checkpoint inhibitors (ICIs).
29. Is there a role for surgery after chemotherapy in recurrent/metastatic adrenal cortical cancer (ACC)?
30. Test performance and clinical validity of circulating tumor DNA (ctDNA) in predicting relapse in solid tumors treated with curative intent therapy.
31. Three-year disease-free survival in randomized trials of chemotherapy and HER2-targeted therapy: A meta-analysis.
32. Impact of proactive symptom monitoring on quality of life (QoL) and treatment toxicity in patients with cancer receiving chemotherapy: A meta-analysis of randomized clinical trials.
33. Leukemia Cutis: A Rare Initial Presentation of Chronic Lymphocytic Leukemia
34. The role of cytoreductive nephrectomy and systemic therapy in the management of tumor thrombus in patients with metastatic renal cell carcinoma.
35. The survival outcomes of the metastatic renal cell carcinoma with rhabdoid differentiation in immunotherapy era: Princess Margaret Cancer Center experience.
36. Survival outcomes of metastatic renal cell carcinoma (mRCC) with sarcomatoid differentiation (SD): A single-institutional experience and literature meta-analysis.
37. Authors' reply to Arun, Biswas et al., and Ganguly et al.
38. ASO Visual Abstract: Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center
39. ASO Author Reflections: Germline Testing for All Patients With Breast Cancer: Has the Time Finally Come?
40. Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center
41. Near-complete response to low-dose ceritinib in recurrent infantile inflammatory myofibroblastic tumour
42. Imaging and Pathological Features of Alveolar Soft Part Sarcoma: Analysis of 16 Patients
43. Late effects in pediatric Hodgkin lymphoma survivors after uniform treatment with ABVD with or without radiotherapy
44. Letter to the Editor: Immune Checkpoint Inhibitors in Alveolar Soft Part Sarcoma: New Standard of Care?
45. Current status of systemic therapy in head and neck cancer
46. Trabectedin in Advanced Sarcomas—Experience at a Tertiary Care Center and Review of Literature
47. Sustained complete response on crizotinib in primary lung inflammatory myofibroblastic tumor - Case report and literature review
48. Recurrent infantile inflammatory myofibroblastic tumor of mesentery––Case report and review of imaging findings
49. Current status of systemic therapy in head and neck cancer.
50. Short-duration adjuvant trastuzumab therapy in human epidermal growth factor receptor 2-positive breast cancers: Has its time come?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.